MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025 [Yahoo! Finance]
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
MediWound Ltd. (NASDAQ: MDWD) had its price target lowered by analysts at HC Wainwright from $28.00 to $25.00. They now have a "buy" rating on the stock.
MediWound Ltd (MDWD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]